If you have been reading about NR1D1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-18. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
== See also == Alim-Louis Benabid Brain computer interfacing (BCI) BrainGate International Neuromodulation Society Interventional pain management North American Neuromodulation Society Neuroimmunology Neuromodulation (journal) Neuroprosthetics Neurotechnology Neurotherapy Neurostimulation Non-invasive cerebellar stimulation Optogenetics Visual prosthesis
=== Urban runoff === Urban runoff is rainwater that runs through streets, gardens, and other urban surfaces, picking up various pollutants along the way. These pollutants can include CEC like microplastics from synthetic materials, polycyclic aromatic hydrocarbons (PAHs) from vehicle exhausts, and pharmaceuticals from improperly disposed medications. This untreated runoff can enter storm drains and eventually discharge into natural water bodies, often bypassing wastewater treatment facilities and leading to their accumulation in the environment, where they can cause harm to wildlife and potentially enter the human food chain. Permeable pavements and rain gardens are being implemented and tested in some urban areas to mitigate the effects of runoff, helping to filter pollutants before they reach the water system.
In 2018, Schleip spearheaded the Fascial Net Plastination Project (FNPP), ananatomical research initiative designed to plastinate and study the human fascial network. The FNPP brought together experts in anatomy, dissection, and plastination, to plastinate a complete human fascia specimen. The project created a full-body human fascia plastinate named FR:EIA (Fascia Revealed: Educating Interconnected Anatomy). FR:EIA was unveiled at the 2021 Fascia Research Congress and is currently on display at the Body Worlds exhibition in Berlin.
== Block copolymer micelles == The concept of micelles was introduced to describe the core-corona aggregates of small surfactant molecules, however it has also extended to describe aggregates of amphiphilic block copolymers in selective solvents. It is important to know the difference between these two systems. The major difference between these two types of aggregates is in the size of their building blocks. Surfactant molecules have a molecular weight which is generally of a few hundreds of grams per mole while block copolymers are generally one or two orders of magnitude larger. Moreover, thanks to the larger hydrophilic and hydrophobic parts, block copolymers can have a much more pronounced amphiphilic nature when compared to surfactant molecules. Because of these differences in the building blocks, some block copolymer micelles behave like surfactant ones, while others do not. It is necessary therefore to make a distinction between the two situations. The former ones will belong to the dynamic micelles while the latter will be called kinetically frozen micelles.
In 2020, Chen Xiaojiang was appointed as head of the National Ethnic Affairs Commission, the first Han Chinese head of the body since 1954. On 24 June 2022, Pan Yue, another Han Chinese, became the head of the commission, with him reportedly holding assimilationist policies toward ethnic minorities. Xi outlined his official views relations between the majority Han Chinese and ethnic minorities by saying "[n]either Han chauvinism nor local ethnic chauvinism is conducive to the development of a community for the Chinese nation." Xi's policies toward ethnic minorities were codified in the Law on Promoting Ethnic Unity and Progress in 2026.
Sources: en.wikipedia.org
== Controversies == Quest Diagnostics set a record in April 2009 when it paid $302 million to the government to settle a Medicare fraud case alleging the company sold faulty medical testing kits. It was the largest qui tam (whistleblower) settlement paid by a medical laboratory for manufacturing and distributing a faulty product. In May 2011, Quest paid $241 million to the state of California to settle a False Claims Act case that alleged the company had overcharged Medi-Cal, the state's Medicaid program, and provided illegal kickbacks as incentives for healthcare providers to use Quest labs. In 2018, Quest Diagnostics was among a number of U.S.–based laboratories linked to inaccuracies of over 200 women's cervical smear tests for CervicalCheck, Ireland's national screening program. Audits of the testing performed by Quest (and another subcontractor, Clinical Pathology Laboratories, Inc. of Austin, Texas) showed a high rate of errors in analysis of samples which led to lawsuits and a government inquiry. Quest and the Irish government continue to settle the resulting lawsuits. On June 3, 2019, Quest announced that American Medical Collection Agency (AMCA), a billing collections service provider, had informed Quest Diagnostics that an unauthorized user had access to AMCA’s system containing personal information AMCA received from various entities, including from Quest. AMCA provides billing collections services to Optum360, which in turn is a Quest contractor. AMCA later went bankrupt after the breach.
The Bergmann azlactone peptide synthesis is a classic organic synthesis process for the preparation of dipeptides. In the presence of a base, peptides are formed by aminolysis of N-carboxyanhydrides of amino acids with amino acid esters (1).
Other scientists have pointed out that the ratio of oxygen isotopes in the fossils today does not necessarily represent the same ratio in the distant past, and may have been altered during or after fossilization (diagenesis). Barrick and Showers have defended their conclusions in subsequent papers, finding similar results in another theropod dinosaur from a different continent and tens of millions of years earlier in time (Giganotosaurus). Ornithischian dinosaurs also showed evidence of homeothermy, while varanid lizards from the same formation did not. In 2022, Wiemann and colleagues used a different approach—the spectroscopy of lipoxidation signals, which are byproducts of oxidative phosphorylation and correlate with metabolic rates—to show that various dinosaur genera including Tyrannosaurus had endothermic metabolisms, on par with that of modern birds and higher than that of mammals. They also suggested that such a metabolism was ancestrally common to all dinosaurs. Even if T. rex does exhibit evidence of homeothermy, it does not necessarily mean that it was endothermic. Such thermoregulation may also be explained by gigantothermy, as in some living sea turtles. Similar to contemporary crocodilians, openings (dorsotemporal fenestrae) in the skull roofs of Tyrannosaurus may have aided thermoregulation. Isotopic analysis found T. rex had a body temperature of 36.3 °C (97.3 °F) ± 2.5 °C, suggesting it had an endothermic metabolism. Its endothermic metabolism suggests it could have inhabited cooler, higher latitude environments.
PUFA-fortified foods available on the market have been increasing since epidemiological and clinical researches have revealed possible effects of PUFA on brain development and curative and/or preventive effects on cardiovascular disease. However, PUFA are very labile and easily oxidizable, thus the maximum beneficial effects of PUFA supplements may not be obtained if they contain significant amounts of toxic OαβUAs, which as commented on above, are being considered as possible causal agents of numerous diseases. Special attention must also be paid to cooking oils used repeatedly in catering and households because in those processes very high amounts of OαβUAs are generated and they can be easily absorbed through the diet.
Sources: en.wikipedia.org
== Plot == A doctor informs fourth grader Eric Cartman and his mother Liane that his obesity is a threat to his health. When Liane says that proper diet and exercise has not worked for him, the doctor recommends a diabetes drug called semaglutide, which has been shown to help people lose weight. This prompts Cartman to fantasize about being able to viciously insult people with impunity without fear of being mocked for his weight, and even going all the way to Pakistan to continue this. However, insurance companies only cover the drug for diabetes, and are too expensive for Liane. The doctor prescribes that Cartman listen to the music of Lizzo, who frequently encourages body positivity. This leaves Cartman despondent, so his friends, Butters Stotch and Kyle Broflovski, accompany him to an insurance company office. However, when they request to make a claim with a dejected-looking claims officer, they are sent on a labyrinthine journey through the bureaucracy of the American health care system. They ultimately decide to make it themselves after learning the raw semaglutide powder can be purchased cheaply from a factory in India and mixed with biostatic water purchased locally. Their other friends, Stan Marsh and Kenny McCormick, join them in this scheme. Meanwhile, Randy Marsh observes many local mothers wearing crop-tops after attaining toned midriffs after losing weight with semaglutide, a recurring visual gag in the episode.
=== Metabolism === The hepatic metabolism of hexobarbital (HB) can be divided into different pathways all forming different metabolites. The S(+) enantiomer of HB preferentially metabolizes into β-3'-hydroxyhexobarbital and the R(-) enantiomer preferentially metabolizes into α-3'-hydroxyhexobarbital, the reaction thus is stereoselective. Both enantiomers, however, form both α- and β-isomers. In total four enantiomers for 3'-hydroxyhexobarbital (3HHB) can be metabolized. This reaction is catalyzed by a cytochrome P450, CYP2B1. All 3HHB isomers formed can undergo further metabolism via glucuronidation or dehydrogenation. If 3HHB undergoes a glucuronidation reaction, via UDP-glucuronosyl transferases (UGTs), it is readily excreted. 3HHB can also undergo dehydrogenation, forming a reactive ketone, 3'-oxohexobarbital (3OHB). The biotransformation of 3HHB into 3OHB is via the enzyme 3HHB dehydrogenase (3HBD), a NAD(P)+ linked oxidation. This enzyme is part of the aldo-keto reductase (AKR) superfamily. In humans, 3HBD has a high preference for NAD+. These reactions are also stereospecific, the R(-) conformation preferentially forms 3OHB as 3HBD has the highest activity for this enantiomer in both alpha and beta form. New evidence proved the further metabolism of 3OHB into 1,5-dimethylbarbituric acid and a cyclohexenone glutathione adduct. This biotransformation step takes place via an epoxide-diol mechanism. The formation of a reactive epoxide, leads to the formation of the compounds mentioned.
==== Appointment ==== On 25 November 2022, the day after Pedro Castillo's speech, the latter decided to appoint the Minister of Culture Betssy Chávez as President of the Council of Ministers of Peru. On the same day, the President and the President of the council announced the formation and composition of the Cabinet, the fifth of Castillo's presidency in one year and three months of office.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.